This approach isolates any adverse effects to the new agent rather than conflating them with tirzepatide's known tolerability profile
Adding 0.5 mL gives 10 mg/mL, which works but produces smaller draw volumes that are slightly harder to measure on larger syringes
Murphy G
Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
It also notes age eligibility varies by state, with most requiring 18 or older and some restricting to 21 or older, and that some states authorize semaglutide first while requiring step therapy before tirzepatide is approved
For elite athletes pushing through training despite reduced appetite, even small improvements in stomach comfort can make a noticeable difference
